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Abstract Respiratory viruses are a major public health
problem because of their prevalence and high morbidity
rate leading to considerable social and economic implica-
tions. Cranberry has therapeutic potential attributed to a
comprehensive list of phytochemicals including antho-
cyanins, flavonols, and unique A-type proanthocyanidins.
Soy flavonoids, including isoflavones, have demonstrated
anti-viral effects in vitro and in vivo. Recently, it was
demonstrated that edible proteins can efficiently sorb and
concentrate cranberry polyphenols, including anthocyanins
and proanthocyanins, providing greatly stabilized matrices
suitable for food products. The combination of cranberry
and soy phytoactives may be an effective dietary anti-viral
resource. Anti-viral properties of both cranberry juice-en-
riched and cranberry pomace polyphenol-enriched soy
protein isolate (CB-SPI and CBP-SPI) were tested against
influenza viruses (H7N1, H5N3, H3N2), Newcastle disease
virus and Sendai virus in vitro and in ovo. In our experi-
ments, preincubation with CB-SPI or CBP-SPI resulted in
inhibition of virus adsorption to chicken red blood cells and
reduction in virus nucleic acid content up to 16-fold, how-
ever, CB-SPI and CBP-SPI did not affect hemagglutination.
Additionally, CB-SPI and CBP-SPI inhibited viral replica-
tion and infectivity more effectively than the commercially
available anti-viral drug Amizon. Results suggest CB-SPI
and CBP-SPI may have preventative and therapeutic
potential against viral infections that cause diseases of the
respiratory and gastro-intestinal tract.
Keywords Cranberry  Polyphenols  Flavonoids 
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Introduction
Food deficiencies occur worldwide every year, increasing
urgency for nutritional interventions with functional foods.
In all countries of the world, nutritional deficiencies are
prevalent for major food substances: proteins, unsaturated
fats, complex carbohydrates, vitamins and minerals.
Functional food ingredients combining basic nutrients and
phytoactive plant extracts can alleviate these deficiencies in
safe and practical food products.
By definition, functional food is a food given an additional
function (often one related to health-promotion or disease
prevention) by adding new ingredients or more of existing
ingredients. Therefore, functional food development is of
great interest to consumers, industries, governments and
universities [2]. There is a need for the development of shelf
stable functional food products enriched with essential
micronutrients and bioactive compounds.
Cranberry is an attractive candidate for the creation of
new types of functional foods. North American cranberry
(Vaccinium macrocarpon Ait) was cultivated since the
early 1800’s and mostly sold as fresh fruits and sauces until
1950. Today cranberries are mostly consumed as processed
products including juices, juice cocktails, sauces and
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sweetened-dried fruits [41]. Cranberry contains a wide
array of polyphenolic compounds [38] including up to 17
different anthocyanins, as well as proanthocyanidins [13],
which are an excellent source of antioxidants, and are
associated with multiple human health benefits, including
prevention of urinary tract infections [35, 40], and lowering
the risk of cardiovascular disease and cancer [29]. Addi-
tionally, anti-viral properties of cranberry constituents have
been recently demonstrated [20, 23, 42].
Cranberry fruits are recognized for their tart, astringent
flavor, and unsweetened cranberry juice is unpalatable to
the majority of consumers. Furthermore, it has been
demonstrated that processing of cranberry into dietary
supplements impacts proanthocyanidins, that are vulnerable
to heat or oxidation [14]. Delivering intact and biologically-
active cranberry phytochemicals in a palatable food matrix
may provide health benefits to the general population and
especially children. It has been recently reported that
defatted soybean flour is an efficient matrix for sorption and
concentration of anthocyanins and other polyphenols, but
not sugars, from cranberry and blueberry juice [31].
Anthocyanins, proanthocyanidins, and flavonols were sta-
bilized and preserved in cranberry polyphenol-enriched
matrices of soy, pea, and hemp proteins, as well as peanut
and soy flour [15, 31, 32]. Complexation with protein
matrices did not alter the chemical composition of cran-
berry phytochemicals. Additionally, cranberry polyphenol
enriched matrices showed both gram positive and gram
negative anti-bacterial activities [15, 31]. Soy isoflavones,
compounds in the flavonoid class of polyphenols, have also
demonstrated anti-viral effects in vitro and in vivo [1].
Respiratory viruses are a major public health problem
because of their prevalence and high morbidity rate leading to
considerable social and economic implications. Substantial
influenza burden remains despite expanded recommendations
for vaccine [26] and anti-viral agent use [27]. There is rec-
ognized urgency in developing anti-viral agents with new
mechanisms of action, and in continuing the work on new
inhibitors directed against influenza polymerase, hemagglu-
tinin, M gene, and other targets [3]. The combined application
of natural viral inhibitors may be used successfully to
potentiate anti-viral efficacy and may enable medication dose
reduction. The aim of our research was to evaluate the anti-
viral properties of a novel functional food ingredient—a
cranberry-polyphenol enriched soy protein powder.
Materials and methods
Materials
Phosphate buffered saline (PBS, pH 7.4) was purchased
from Amresco (Solon, OH, USA). 10-day-old chicken eggs
and 50 % chicken red blood cell (cRBC) suspensions were
obtained from Almaty chicken factory farm (Almaty,
Kazakhstan). All water used in the experiments was puri-
fied using an E-pure water purification system with the
minimum resistivity of 17.6 MX cm (Barnstead, Dubuque,
IA). Anti-viral medication Amizon (Amizonum, Farmak
Ltd, Ukraine) served as a positive control. Amizon or
l-methyl-4-(benzylaminocarbonyl) pyridinium iodide [4],
CAS Registry Number: 201349-37-3 is a low toxicity
compound with well established anti-viral properties [22]
that has been used for influenza prophylaxis and treatment.
Tamiflu (F. Hoffmann-La Roshe Ltd., Switzerland) and
Rimantadine (OlainFarm, Latvia) were used in study of
orthomyxoviruses only.
Cranberry polyphenol enriched soy protein matrices
Cranberry polyphenol enriched soy protein matrices were
produced as described in detail previously [31] with
minor modifications. Total polyphenols were determined
by Folin-Ciocalteu method [36] and reported as gallic
acid equivalents. Briefly, cranberry juice concentrate
(Fruit Smart, Grandview, WA) was diluted 4 to 5-fold
depending on total polyphenolic content of starting
material. The diluted juice was mixed with soy protein
isolate (ADM, Decatur, IL) at 10:1 (v/w) ratio. The
mixture was adjusted to pH 2 and centrifuged for 10 min
at 4000 rpm to separate solid from liquid. The solid
matrix was lyophilized to produce a dry powder, CB-SPI,
containing 3 % total polyphenols sorbed onto the protein
matrix. Total polyphenols were determined by quantifying
the difference between the total polyphenol content before
and after sorption divided by the dry weight of CB-SPI to
obtain mg polyphenols per gram SPI. Proanthocyanidin
composition of CB-SPI was previously described [15].
CB-SPI was dispersed in PBS to concentrations indicated
in experiments.
To produce the cranberry pomace extract, frozen
depectinized cranberry pomace (BNK, Wisconsin Rapids,
WI) was blended with 50 % ethanol at a 5:1 ratio (v/w) and
pH adjusted to 2. The mixture was incubated in a rotating
flask immersed in an 80 C water bath for 2 h, centrifuged
at 4000 rpm for 10 min and supernatant was filtered
through Miracloth (Calbiochem, EMD Millipore, Darm-
stadt, Germany). Total polyphenols were quantified as
described above. Extracts were combined with a calculated
amount of SPI and dried to produce CBP-SPI containing
10 % total polyphenols sorbed onto the protein matrix
during the co-drying process. Lyophilized CBP-SPI was
dispersed in PBS to desired concentrations and used for
anti-viral experiments. Phytochemical-enriched protein
CBP-SPI has been characterized in detail, previously [32].
124 A. S. Turmagambetova et al.
123
Viruses
A group of viruses commonly used in medical and vet-
erinary research was selected to cover different aspects of
viral pathogenesis. Sendai virus is frequently used as a
model for entry of enveloped viruses into animal cells [6,
21]. Newcastle Disease Virus has well researched anti-
neoplastic and pleiotropic immune responses [17]. Influ-
enza virus can cause intestine diseases. Orthomyxoviruses:
highly pathogenic avian influenza virus, A/FPV/Rostock/
34 (H7N1) and avian influenza virus A/Tern/South Africa/
1/61 (H5N3), and paramyxoviruses, Sendai virus (strain
960) and Newcastle disease virus (strain Beadetta) were
obtained from the state collection of viruses at Ivanovsky
Institute of Virology (Moscow, Russia). Orthomyxovirus
A/Almaty/8/98 (H3N2) was obtained from the collection of
microorganisms at the Research Institute for Biological
Safety Problems (Kazakhstan).
Macrophages and MDCK cells
Bone marrow cell suspensions recovered from tibias and
femurs of mice were suspended in DMEM medium (Gibco,
Life Technologies) containing 4 g/L glucose, 1 mM pyru-
vate and 3.97 mM L-alanyl-L-Glutamine, 10 % heat-inac-
tivated fetal calf serum (FCS, Dominique Dutscher SAS),
streptomycin (50 lg/mL) and penicillin (50 IU/mL) (Bio-
chrom AG, IBS International) and 50 ng/mL recombinant
mouse CSF-1 (rmCSF-1) (ImmunoTools, Germany). Cells
were distributed in bacteriologic plastic flasks (Corning
Life Science, 7 9 105 cells/ml) and were incubated at
37 C in a 7.5 % CO2 atmosphere for one day.
Madin–Darby canine kidney (MDCK) cells were
obtained from The Research Institute for Biological Safety
Problems (Kazakhstan). MDCK cells were cultured as
monolayers in the MEM medium (PAA Labaratories
GmbH, Germany) supplemented with 10 % heat-inacti-
vated fetal bovine serum (PAA Labaratories).
Cytotoxicity evaluation
The cytotoxicity evaluation was performed by MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide] method. 33–35 Briefly, 100 lL of each extract/
fraction dilutions (1:2—ranging from 15.6 to 2000 lg/mL
prepared in cell culture medium) was added to each well
with macrophages (106 cells/well). As a control 100 lL of
medium was added to cells. Plates were incubated under
the same conditions for 4 h. After 4 h, the medium was
removed by suction from all wells and 50 lL of MTT
(Sigma, 1 mg/mL) solution prepared in cell culture med-
ium were added to each well and the plates were incubated
once more for 2 h. After the MTT solution was removed
without disturbing the cells, 50 lL of DMSO was added to
each well to dissolve the formazan crystals. After gently
shaking the plates, the crystals were completely dissolved,
and absorbances were read on a multi-well spectropho-
tometer (SunriseTM, Tecan) at 540 nm. The CC50 was
defined as the cytotoxic concentration of each sample that
reduced the absorbance of treated cells to 50 % when
compared with that of the control.
Chicken embryo lethality assay
The CB-SPI and CBP-SPI preparations were each diluted
to the following concentrations: 50, 25, 12, 6, 3, 1.5 and
0.75 mg/ml in sterile PBS. A single dose of 100 lL of each
dilution was inoculated into the allantoic cavity of 10-day-
old embryonated chicken eggs of seven serial groups
according to their concentrations; a control group was
inoculated with sterile PBS. The eggs were incubated in a
humidified incubator at 37 C for 5 days, and embryo
death was recorded.
Virus yield reduction assay
CB-SPI and CBP-SPI were tested for in ovo anti-viral
activity. A mixture containing 100 ll of influenza virus,
corresponding to 100 EID50/ml, and 100 ll of PBS (con-
trol) or CBP-SPI or CB-SPI, with final doses of 0.05, 0.5
and 5.0 mg per chicken embryo, were incubated for 30 min
at 37 C and used to inoculate 10-day-old fertilized
chicken eggs by the allantoic route. Five replicates of each
assay were performed in three independent experiments.
Inoculated eggs were incubated at 37 C in a humidified
incubator. After incubation for 24–72 h, eggs were chilled
for 12 h at 4 C, the allantoic fluid was harvested and used
for HA titer. Five dilutions were tested, and the effective
anti-viral concentration determined by regression analysis.
Virucidal assay
Equal volumes of viral inocula and 50 mg/ml CB-SPI or
CBP-SPI (5 % w/v) were mixed and incubated for 30 min
at room temperature. The mixture was titrated by tenfold
dilutions and used to inoculate 10-day-old fertilized
chicken eggs by the allantoic route. After incubation for
24–72 h at 37 C in a humidified incubator, EID50 was
determined as described by Reed and Muench [30]. A viral
inoculum, treated with medium without cranberry
polyphenol-enriched matrices, was used as control for each
virus. Infectivity suppression was expressed as the differ-
ence between log10 (EID50 treatment) and log10 (EID50 control).
Three independent experiments with triplicate treatments
were performed.
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Hemagglutination assay
Hemagglutination assay is a commonly used method of
influenza virus titration [18]. Two-fold serial dilutions of
virus were made in 50 ll PBS using U-shaped 96-well
microtiter plates. 50 ll of a 0.75 % suspension of cRBCs
were added to each well and mixed by gentle agitation.
The plate was incubated at room temperature until control
wells showed complete settling of cRBCs. Wells with
complete HA were recorded as positive for HA and wells
with a distinct button formation were recorded as negative
for HA. The HA titer was read as the reciprocal of the
dilution of virus in the last well showing complete HA
[11, 19].
Hemagglutination inhibition assay
The assay was carried out using influenza viruses (H7N1,
H3N2, H5N3), Newcastle disease virus, and Sendai virus
according to a method described by Pedersen [25] with
some modifications. Hemagglutination inhibition assay
was performed to evaluate the effects of CB-SPI and CBP-
SPI preparations on viral adsorption to target cells,
demonstrating interference on hemagglutination. Stan-
dardized cRBC solutions were prepared according to
Pedersen [25]. The influenza virus solution, 50 ll, was
mixed with an equal volume of CB-SPI or CBP-SPI
(50 lL) in two-fold serial dilutions in PBS and incubated
for 1 h at 4 C. Next, the solution was mixed with an equal
volume of a 0.75 % cRBC suspension (50 ll) and incu-
bated for 1 h at room temperature. HA titer was calculated
as the reciprocal of the highest dilution that produced
complete HA. Assays were done in triplicate and three
independent experiments were performed.
Inhibition of virus adsorption
The inhibition of virus adsorption assay was performed to
evaluate the effects of both CB-SPI and CBP-SPI on viral
adsorption to target cells. Standardized 5 % cRBC solu-
tions were prepared according to Pedersen [25]. The
influenza virus solution, 50 ll, was mixed with an equal
volume of CB-SPI or CBP-SPI in a two-fold serial dilu-
tion in PBS. After incubation for 30 min at 4 C, 209
volume of 5 % cRBC solution was added to each tube.
After incubation for an additional 30 min at 4 C, the
mixture was centrifuged at 3000 rpm for 5 min and
supernatant was used for the hemagglutination assay titer.
Positive controls contained virus solutions and cells and
negative controls contained saline and cells [34, 37].
Assays were done in triplicate and three independent
experiments were performed.
Interaction of CB-SPI and CBP-SPI with virus
Equal volumes (300 ll) of allantoic virus, 108 EID50, and
2 % of preparations were mixed and incubated for 30 min
at 4 C. The mixture was centrifuged at 6000 rpm for
5 min and supernatant was used for real time-PCR quan-
tification of viral RNA [5].
RNA was extracted from supernatant liquid using
RNeasy Mini Kit (QIAGEN, Hilden, Germany) according
to the manufacturer’s instructions. The RNA was converted
to full-length cDNA in the following reaction: 2.5 ll of
DMPC (di-methyl pyrocarbonate) water, 5 ll of 59 First
Strand buffer (Invitrogen), 0.5 ll of 10 mMdNTP mix
(Amersham Biosciences), 2 ll of 50 mM UNi12 primer,
32 U of RNAguard (Amersham Biosciences), 200 U of
MMLV reverse transcriptase (Invitrogen) and 5 ll RNA
solution in total volume of 25 ll. Reactions were incubated
at 42 C for 60 min followed by inactivation of the enzyme
at 95 C for 5 min. PCR amplification with HA gene
specific primers (Forward primer: 50-AGCAAAAGCAGG
GGA-30, Reverse primer: 50-AGTAGAAACAAGGGTGT
T-30) was performed on the PikoReal 96 Real Time PCR
System (Thermo Scientific, USA) to amplify the product
containing the fragment HA gene. The PCR mix contained:
SybrGreen mix 10 ll (Thermo Scientific), 240 nM each of
forward primer and reverse primer, ROX 0.04 ll and 5 ll
cDNA for a 20 ll reaction volume. Reactions were placed
in a thermal cycler at 94 C for 2 min, then cycled 35 times
between 94 C 60 s, annealing at 48 C for 60 s, and
elongation at 72 C for 180 s and finally kept at 8 C until
later use.
Statistical analysis
Results were expressed as mean ± SD of three indepen-
dent experiments, unless otherwise noted. One-way
ANOVA was used to evaluate the difference between the
test samples. Student’s unpaired t test was used to evaluate
the difference between the test sample and untreated con-
trol. A p value\0.05 was considered statistically signifi-
cant. GraphPad PRISM software (La Jolla, CA) was used
for statistical analysis.
Results
Cytotoxicity and chicken embryo lethality of CB-SPI
and CBP-SPI
Cytotoxic concentrations (CC50) of cranberry juice con-
centrate, SPI, CB-SPI and SBP-SPI are presented in
Table 1. For both CB-SPI and CBP-SPI CC50 exceeded
500 lg/mL in macrophages and CC50 exceeded 400 lg/mL
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in MDCK cells. These cytotoxicity levels are significantly
lower that the cytotoxicity of cranberry juice concentrate as
well as many plant extracts evaluated for antiviral prop-
erties. For SPI, the CC50 was lower than for the polyphenol
enriched matrices: 500 and 390 lg/mL for macrophage and
MDCK cells, respectively. For cranberry juice concentrate,
the CC50 were 150 and 130 lg/mL for macrophage and
MDCK cells, respectively.
Chicken embryo lethality assay showed that cranberry
juice or cranberry pomace polyphenol-enriched soy protein
isolate (CB-SPI or CBP-SPI) had no toxicity in the con-
centration range investigated. LD50 for tested preparations
exceed 100 mg per chicken embryo.
Thus, the combination of SPI with cranberry antho-
cyanins reduced the potential cytotoxic effects of the initial
ingredients.
Effect of CB-SPI and CBP-SPI on virus yield
reduction
The commercial anti-viral agents Rimantadine and Tamiflu
were not used in experiments with paramyxoviruses, since
they are affecting only the influenza virus. Amizon is an
anti-viral agent usually used for the treatment of DNA and
RNA containing viruses (HSV, hepatitis and mumps)
therefore in our experiments we used this drug.
Preincubation with CB-SPI or CBP-SPI suppressed the
reproduction of 100 EID50 (fifty percent embryo infectious
dose) of ortho- and paramyxoviruses [19]. The investigated
doses of CB-SPI and CBP-SPI ranged from 0 to 5 mg per
chicken embryo (or from 0 to 100 mg per kg of embryo
weight). A 5 mg dose of CB-SPI or CBP-SPI per embryo
led to the suppression of reproduction of 100 EID50 of the
virus from 24 - 90 %, depending on the virus (Fig. 1). For
orthomyxoviruses, suppression of virus reproduction was
greatest for H5N3, followed by H3N2, and H7N1. Both
paramyxoviruses were affected in a similar manner. Anti-
viral properties of CB-SPI and CBP-SPI were compared to
activity of the commercial anti-viral agents Amizon,
Rimantadine and Tamiflu. Anti-viral activity of CB-SPI
and CBP-SPI against orthomyxoviruses was lower com-
pared to Tamiflu and Rimantadine (Fig. 1 A). It may be
due to the different mechanisms of action of these sub-
stances on the influenza virus. Amizon inhibits virus
reproduction by changing the homeostasis of an organism
which is a possible mechanism of action of investigated
enterosorbents (CB-SPI and CBP-SPI). Anti-viral activity
of CB-SPI compared to Amizon was stronger against
orthomyxoviruses (Fig. 1a) but weaker against paramyx-
oviruses (Fig. 1b). Suppression of all viruses was signifi-
cantly greater with CBP-SPI compared with Amizon
(Fig. 1).
It was shown that the anti-viral activity of CB was
slightly higher than CB-SPI against orthomyxoviruses and
paramyxoviruses. At the same time CB-SPI was much
more stable than CB, indicating that it could retain anti-
viral efficacy after a long storage (up to 24 months). Total
polyphenols sorbed onto the protein matrix were 3 % into
CB-SPI and 10 % into CBP-SPI, consequently anti-viral
activity of CBP-SPI was higher because of the higher
content of chemically active substances.
Virucidal activity of CB-SPI and CBP-SPI
Cranberry polyphenol enriched soy protein matrices sup-
pressed virus infectivity ranging from 0.48 to 1.59 lg which
corresponds from 50 to 90 % of infectious viral particles
(Fig. 2). Results show pronounced anti-viral properties of
CB-SPI and CBP-SPI which exceeded the virucidal activity
of Amizon against orthomyxoviruses, H7N1, H3N2, and
H5N3. CBP-SPI, but not CB-SPI, also demonstrated sig-
nificantly greater suppression of infectivity of paramyx-
oviruses, Newcastle disease virus and Sendai virus,
compared to Amizon.
Effect of CB-SPI and CBP-SPI on hemagglutination
of viruses
Influenza virus titration using the hemagglutination assay
confirmed viability of all strains used in the experiments
(data not shown). The effect on hemagglutination by
preincubation with CB-SPI and CBP-SPI concentrations
ranging from 0 to 2.5 % was evaluated for influenza
Table 1 Cytotoxicity of the
tested preparations
Preparation CC50 (lg/mL) for macrophages CC50 (lg/mL) for MDCK
CB 150 ± 32 130 ± 32
SPI 500 ± 34 390 ± 34
CB-SPI 520 ± 46 425 ± 46
CBP-SPI 525 ± 34 438 ± 34
CB cranberry juice concentrate; SPI soy protein isolate; CB-SPI cranberry juice polyphenols sorbed onto
soy protein matrix; CBP-SPI cranberry pomace extract polyphenols sorbed onto soy protein matrix
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Fig. 1 Suppression of virus production by CB-SPI and CBP-SPI.
Doses of 0,05; 0,5 and 5,0 mg per chicken embryo are presented.
a orthomyxoviruses; b paramyxoviruses. Error bars represent SD for
n = 15. * Statistically significant difference (p\ 0.05) compared to
Amizon
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viruses (H7N1, H3N2, H5N3), Newcastle disease virus and
Sendai virus. We detected no significant differences in
hemagglutination (data not shown). These results indicated
that CB-SPI and CBP-SPI did not directly interfere with
binding of viruses to cell surface receptors.
Inhibition of virus adsorption by CB-SPI and CBP-
SPI
The effect of CB-SPI and CBP-SPI on virus adsorption
was evaluated in cRBCs. Preincubation of ortho- and
paramyxoviruses with CB-SPI and CBP-SPI reduced
adsorption of viruses to target cells in a concentration
dependent manner (data not shown). At a high concentra-
tion of 2.5 % we observed 40–70 % inhibition of virus
adsorption.
Effect of CB-SPI and CBP-SPI on viral RNA
abundance
Real-time qPCR was used to quantify residual viral RNA
in suspension after preincubation with CB-SPI or CBP-SPI.
It was demonstrated that preincubation with CB-SPI and
CBP-SPI reduced the number of virus nucleic acid copies
by eightfold (average of 4 replicates Ct ± SD; 18.15 ±
0.13) and 16-fold (19.42 ± 0.42), respectively, compared
to control (15.28 ± 0.24) (Fig. 3).
Discussion
Health effects of cranberry, cranberry products, and iso-
lated cranberry components in humans and animals are
debated. Recently, a number of studies have pointed out
Fig. 2 Suppression of virus
infectivity by CB-SPI and CBP-
SPI A dose of 5 mg per chicken
embryo is presented. Error bars
represent SD for n = 9.
* Statistically significant
difference (p\ 0.05) compared
to Amizon
Fig. 3 Inhibition of level of
viral RNA in suspension after
preincubation with CB-SPI and
CBP-SPI
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that cranberry A-type proanthocyanidins exhibit unique
microbial anti-adhesion properties [16]. It was reported that
cranberry metabolites inhibit adhesive abilities rather than
kill bacteria. Evidence of protection from cancer, cardio-
vascular disease, and inflammation by cranberry phyto-
chemicals is growing, while neuroprotection and anti-viral
activity also have begun to draw new consideration. Soy
protein isolate phytochemicals include fatty acids, saponins
and isoflavones [8]. Isoflavones are the most studied
bioactives of soybeans and have demonstrated anti-viral
effects, including inhibition of infectivity, on a wide range
of human viruses [1].
Our data suggest that cranberry compounds, most likely
polyphenols, stabilized in an edible protein matrix may
interact with cellular receptors, making it possible to use
cranberry preparations to suppress virus reproduction. Two
glycoproteins of the influenza virus envelope, hemagglu-
tinin and neuraminidase recognize sialic acid. Initiation of
virus infection involves multiple hemagglutinins binding to
sialic acids on carbohydrate side chains of target cell sur-
face glycoproteins and glycolipids [12]. Considerable pro-
gress has been made toward understanding the structural
basis of interaction of the two major surface glycoproteins
of influenza A virus with their common ligand/substrate.
Carbohydrate chains terminating in sialic acid that bind
hemagglutinins are attractive targets for anti-viral agent
development. Cranberry phytochemicals may also bind
hemagglutinins and prevent initiation of infection.
Cranberry phytochemical components include phenolic
acids, benzoates, hydroxycinnamic acids, terpenes and
organic acids. Flavonoids, especially anthocyanins, flavo-
nols, and proanthocyanidins, have attracted research
attention [24]. Cranberry proanthocyanidins have unusual
A-type linkages [9, 10] compared to the more common
B-type linkages found in other tannin-rich foods. Phyto-
chemical analyses indicated that cranberry proanthocyani-
dins are composed primarily of oligomers containing a
minimum one A-type interflavan bond [3, 24].
Anti-viral properties of high molecular weight cranberry
compounds were recently discovered [20, 23, 42]. It was
reported that cranberry high molecular weight non-dialyz-
able material (more than 15,000 MW) was significantly
more potent than cranberry proanthocyanidins in inhibiting
hemagglutination [42]. Non-dialyzable material showed
potent activity against neuraminidase in influenza A and B
strains, suggesting therapeutic potential against viral
infections [23]. Su et al. [39] used standardized plaque
assays to demonstrate that cranberry juice and proantho-
cyanidins have significant anti-viral effects on human
enteric viral surrogates murine norovirus (MNV-1), feline
calici virus (FCV-F9), MS2 (ssRNA) bacteriophage, and
phiX-174 (ssDNA). In general, presence of ortho-trihy-
droxyl groups in the B-ring of anthocyanidin was important
in compounds exhibiting anti-HSV. Double interflavan
linkages gave rise to interesting antiviral effects (HSV and
HIV) [7].
In our research, preincubation with CB-SPI or CBP-SPI
in concentrations up to 2.5 % (w/v; 25 mg/mL) did not
affect hemagglutination of ortho- and paramyxoviruses,
hence the anti-viral mode of action of CB-SPI or CBP-SPI
may be other than interference with binding of viruses to
target cell surface receptors.
In this study we demonstrated that CB-SPI and CBP-SPI
inhibited adsorption of viruses to target cells and decreased
reproduction of ortho- and paramyxoviruses in ovo.
Additionally, we demonstrated that virus nucleic acid
content was reduced by eightfold with CB-SPI preincuba-
tion and 16-fold with CBP-SPI preincubation compared to
control. Both matrices are formulated with SPI, thus dif-
ferences in activity are attributed to cranberry polyphenols.
These differences in the activity may be attributed to lower
total polyphenol concentration of CB-SPI (3 % total
polyphenols) compared to CBP-SPI (10 % total polyphe-
nols). This is also applicable to the inhibition of virus
adsorption to cRBCs where CBP-SPI was more effective
than CB-SPI. Adsorption of all tested strains was inhibited
by CBP-SPI or CB-SPI in a dose dependent manner
(Fig. 3).
Suppression of viral reproduction by CBP-SPI signifi-
cantly exceeded that of Amizon whereas suppression of
viral reproduction by CB-SPI was comparable to Amizon
(Fig. 1). At the dose of 5 mg (0.5 mg of total polyphenols)
per chicken embryo CBP-SPI suppressed virus reproduc-
tion in the range of 45–90 % depending on the virus strain.
CBP-SPI suppression of viral reproduction was more pro-
nounced for H5N3 and Sendai virus and Newcastle disease
virus, and lower for H7N1 and H3N2.
Suppression of infectivity of orthomyxoviruses in viru-
cidal experiments was significantly higher for CB-SPI and
CBP-SPI compared to Amizon (Fig. 2). In the case of
paramyxoviruses, virucidal activity of CBP-SPI was sig-
nificantly higher than CB-SPI and Amizon and virucidal
activity of CB-SPI was lower than Amizon. CBP-SPI
virucidal activity was similar in all tested strains. Overall,
our results indicate that CB-SPI and CBP-SPI exhibit
moderate anti-viral properties through prevention of virus
adsorption as well as removal and destruction of virions
from an in vitro host environment.
Our data suggest that soy protein/cranberry polyphenol
complex effectively inhibits adsorption, replication, and
infectivity of ortho- and paramyxoviruses that cause dis-
eases of the respiratory and gastro-intestinal tract [28, 33].
New functionally-enhanced soy proteins may be the basis
for development of novel, food-based therapeutic products.
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